Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:1806-1813
Published online before print April 4, 2005, doi: 10.1161/01.CIR.0000160867.23556.7D
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/14/1806    most recent
01.CIR.0000160867.23556.7Dv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kostenis, E.
Right arrow Articles by Walther, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kostenis, E.
Right arrow Articles by Walther, T.
Related Collections
Right arrow Other myocardial biology
Right arrow Receptor pharmacology
Right arrow Other Vascular biology

(Circulation. 2005;111:1806-1813.)
© 2005 American Heart Association, Inc.


Molecular Cardiology

G-Protein–Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor

Evi Kostenis, PhD; Graeme Milligan, PhD; Arthur Christopoulos, PhD; Carlos F. Sanchez-Ferrer, MD, PhD; Silvia Heringer-Walther, MD, PhD; Patrick M. Sexton, PhD; Florian Gembardt, MPharm; Elaine Kellett, DPhil; Lene Martini, PhD; Patrick Vanderheyden, PhD; Heinz-Peter Schultheiss, MD; Thomas Walther, PhD

From 7TM Pharma (E. Kostenis, L.M.), Hoersholm, Denmark; Molecular Pharmacology Group (G.M., E. Kellett), Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, Scotland; Department of Pharmacology (A.C.) and Howard Florey Institute of Experimental Physiology and Medicine (P.M.S.), The University of Melbourne, Parkville, Victoria, Australia; Department of Pharmacology, Facultad de Medicina, Universidad Autonoma (C.F.S.-F.), Madrid, Spain; Department of Pharmacology, Erasmus Medical Center (S.H.-W., F.G., T.W.), Rotterdam, the Netherlands; Department of Cardiology, Charité Berlin (F.G., H.-P.S., T.W.), Campus Benjamin Franklin, Berlin, Germany; and Department of Molecular and Biochemical Pharmacology (P.V.), Vrije Universiteit Brussel, Brussels, Belgium.

Correspondence to Thomas Walther, PhD, Department of Pharmacology, Erasmus Medical Center, Dr. Molewaterplein 50, 3000 DR Rotterdam, The Netherlands. E-mail t.walther{at}erasmusmc.nl

Received July 25, 2004; revision received November 22, 2004; accepted November 24, 2004.

Background— We previously identified the G-protein–coupled receptor Mas, encoded by the Mas proto-oncogene, as an endogenous receptor for the heptapeptide angiotensin-(1-7); however, the receptor is also suggested to be involved in actions of angiotensin II. We therefore tested whether this could be mediated indirectly through an interaction with the angiotensin II type 1 receptor, AT1.

Methods and Results— In transfected mammalian cells, Mas was not activated by angiotensin II; however, AT1 receptor–mediated, angiotensin II–induced production of inositol phosphates and mobilization of intracellular Ca2+ was diminished by 50% after coexpression of Mas, despite a concomitant increase in angiotensin II binding capacity. Mas and the AT1 receptor formed a constitutive hetero-oligomeric complex that was unaffected by the presence of agonists or antagonists of the 2 receptors. In vivo, Mas acts as an antagonist of the AT1 receptor; mice lacking the Mas gene show enhanced angiotensin II–mediated vasoconstriction in mesenteric microvessels.

Conclusions— These results demonstrate that Mas can hetero-oligomerize with the AT1 receptor and by so doing inhibit the actions of angiotensin II. This is a novel demonstration that a G-protein–coupled receptor acts as a physiological antagonist of a previously characterized receptor. Consequently, the AT1-Mas complex could be of great importance as a target for pharmacological intervention in cardiovascular diseases.


Key Words: angiotensin • calcium • muscle, smooth • vasoconstriction • receptors




This article has been cited by other articles:


Home page
IOVSHome page
A. Vaajanen, H. Vapaatalo, H. Kautiainen, and O. Oksala
Angiotensin (1-7) Reduces Intraocular Pressure in the Normotensive Rabbit Eye
Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2557 - 2562.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
N. Alenina, P. Xu, B. Rentzsch, E. L. Patkin, and M. Bader
Genetically altered animal models for Mas and angiotensin-(1-7)
Exp Physiol, May 1, 2008; 93(5): 528 - 537.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Xu, A. C. Costa-Goncalves, M. Todiras, L. A. Rabelo, W. O. Sampaio, M. M. Moura, S. Sousa Santos, F. C. Luft, M. Bader, V. Gross, et al.
Endothelial Dysfunction and Elevated Blood Pressure in Mas Gene-Deleted Mice
Hypertension, February 1, 2008; 51(2): 574 - 580.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. O. Sampaio, C. Henrique de Castro, R. A.S. Santos, E. L. Schiffrin, and R. M. Touyz
Angiotensin-(1-7) Counterregulates Angiotensin II Signaling in Human Endothelial Cells
Hypertension, December 1, 2007; 50(6): 1093 - 1098.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. C. da Costa Goncalves, R. Leite, R. A. Fraga-Silva, S. V. Pinheiro, A. B. Reis, F. M. Reis, R. M. Touyz, R. C. Webb, N. Alenina, M. Bader, et al.
Evidence that the vasodilator angiotensin-(1 7)-Mas axis plays an important role in erectile function
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2588 - H2596.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. F. Giani, M. M. Gironacci, M. C. Munoz, C. Pena, D. Turyn, and F. P. Dominici
Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1154 - H1163.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. L. Reudelhuber, K. E. Bernstein, and P. Delafontaine
Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?: Time for Another Look
Hypertension, June 1, 2007; 49(6): 1196 - 1201.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich
ACE2 of the heart: From angiotensin I to angiotensin (1-7)
Cardiovasc Res, February 1, 2007; 73(3): 463 - 469.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. O. Sampaio, R. A. Souza dos Santos, R. Faria-Silva, L. T. da Mata Machado, E. L. Schiffrin, and R. M. Touyz
Angiotensin-(1-7) Through Receptor Mas Mediates Endothelial Nitric Oxide Synthase Activation via Akt-Dependent Pathways
Hypertension, January 1, 2007; 49(1): 185 - 192.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Paul, A. Poyan Mehr, and R. Kreutz
Physiology of local Renin-Angiotensin systems.
Physiol Rev, July 1, 2006; 86(3): 747 - 803.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Canals, L. Jenkins, E. Kellett, and G. Milligan
Up-regulation of the Angiotensin II Type 1 Receptor by the MAS Proto-oncogene Is Due to Constitutive Activation of Gq/G11 by MAS
J. Biol. Chem., June 16, 2006; 281(24): 16757 - 16767.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
H. Stepan, R. Faber, N. Dornhofer, B. Huppertz, A. Robitzki, and T. Walther
New Insights into the Biology of Preeclampsia
Biol Reprod, May 1, 2006; 74(5): 772 - 776.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. L. Reudelhuber
A Place in Our Hearts for the Lowly Angiotensin 1-7 Peptide?
Hypertension, May 1, 2006; 47(5): 811 - 815.
[Full Text] [PDF]


Home page
Circ. Res.Home page
I. Fleming
Signaling by the Angiotensin-Converting Enzyme
Circ. Res., April 14, 2006; 98(7): 887 - 896.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Milasta, J. Pediani, S. Appelbe, S. Trim, M. Wyatt, P. Cox, M. Fidock, and G. Milligan
Interactions between the Mas-Related Receptors MrgD and MrgE Alter Signalling and Trafficking of MrgD
Mol. Pharmacol., February 1, 2006; 69(2): 479 - 491.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. M. Ferrario, A. J. Trask, and J. A. Jessup
Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Z. Chen, F. Tan, E. G. Erdos, and P. A. Deddish
Hydrolysis of Angiotensin Peptides by Human Angiotensin I-Converting Enzyme and the Resensitization of B2 Kinin Receptors
Hypertension, December 1, 2005; 46(6): 1368 - 1373.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. H. de Castro, R. A. Souza dos Santos, A. J. Ferreira, M. Bader, N. Alenina, and A. Pinto de Almeida
Evidence for a Functional Interaction of the Angiotensin-(1-7) Receptor Mas With AT1 and AT2 Receptors in the Mouse Heart
Hypertension, October 1, 2005; 46(4): 937 - 942.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Wilson, G. Wilkinson, and G. Milligan
The CXCR1 and CXCR2 Receptors Form Constitutive Homo- and Heterodimers Selectively and with Equal Apparent Affinities
J. Biol. Chem., August 5, 2005; 280(31): 28663 - 28674.
[Abstract] [Full Text] [PDF]